Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15480836 | 1.00 | ALDH1A1 (0.44) | ALDH1A1HPGDSMN1; SMN2GAANAMPT | |
| SCHEMBL15480834 | 1.00 | ALDH1A1 (0.44) | ALDH1A1HPGDSMN1; SMN2GAANAMPT | |
| SCHEMBL15480837 | 1.00 | ALDH1A1 (0.44) | ALDH1A1HPGDSMN1; SMN2GAANAMPT | |
| SCHEMBL14947131 | 0.84 | TDP1 (0.54) | ALDH1A1HPGDSMN1; SMN2KMT2A | |
| SCHEMBL23754645 | 0.82 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL29410885 | 0.81 | NAMPT (0.57) | ALDH1A1HPGDGAANAMPTMAPT | |
| SCHEMBL154607 | 0.80 | HPGD (0.53) | ALDH1A1HPGDGAAMAPTHDAC1 | |
| SCHEMBL15480838 | 0.79 | NAMPT (0.44) | ALDH1A1HPGDSMN1; SMN2NAMPTHDAC1 | |
| Hydrochloric Acid SCHEMBL27871652 | 0.78 | HPGD (0.52) | ALDH1A1HPGDGAAMAPTHDAC1 | |
| Triethylene Glycol SCHEMBL2112665 | 0.78 | TSHR (0.58) | ALDH1A1HPGDSMN1; SMN2GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160113271-A1 | FORMULATION COMPONENT | SYNGENTA LIMITED (GB) | 2016-04-28 | — | — | US | disclosed |
| US-20140051580-A1 | FORMULATION COMPONENT | SYNGENTA LIMITED (GB) | 2014-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160113271-A1 | FORMULATION COMPONENT | BCHE, HRH4, TBCB | ALDH1A1 2068/4885HPGD 1945/4885SMN1; SMN2 3526/4885 |
| US-20140051580-A1 | FORMULATION COMPONENT | BCHE, HRH4, TBCB | ALDH1A1 2068/4885HPGD 1945/4885SMN1; SMN2 3526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.